| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Vibegron (JAN/USAN); Beova (TN); Gemtesa (TN) | ||||||
| Product | GEMTESA (Urovant Sciences) | ||||||
| Formula | C26H28N4O3 | ||||||
| Exact mass | 444.2161 | ||||||
| Mol weight | 444.5255 | ||||||
| Structure |  | ||||||
| Class | Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate Transporter substrate DG01665 ABCB1 substrate | ||||||
| Remark |
| ||||||
| Efficacy | Antidysuria, beta3-Adrenergic receptor agonist | ||||||
| Comment | Treatment of overactive bladder | ||||||
| Target | ADRB3 [HSA:155] [KO:K04143] | ||||||
| Pathway |
| ||||||
| Metabolism | Enzyme: CYP3A4 [HSA:1576] Transporter: ABCB1 [HSA:5243] | ||||||
| Interaction | |||||||
| Brite | USP drug classification [BR:br08302] Genitourinary Agents Antispasmodics, Urinary Vibegron D10433 Vibegron (JAN/USAN) Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 25 Urogenital and anal organ agents 259 Miscellaneous 2590 Miscellaneous D10433 Vibegron (JAN/USAN) Drug groups [BR:br08330] Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D10433 Vibegron Transporter substrate DG01665 ABCB1 substrate D10433 Vibegron Target-based classification of drugs [BR:br08310] G Protein-coupled receptors Rhodopsin family Adrenaline ADRB3 D10433 Vibegron (JAN/USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10433 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10433 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10433 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D10433 Drug transporters D10433 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 33 1 C5a C 25.5500 -16.4500 2 N1b N 24.3600 -15.7500 3 C8y C 23.1700 -16.4500 4 C8x C 21.9800 -15.7500 5 C8x C 20.7200 -16.4500 6 C8y C 20.7200 -17.8500 7 C8x C 21.9100 -18.5500 8 C8x C 23.1700 -17.8500 9 C1b C 19.5300 -18.5500 10 C1y C 18.3400 -17.8500 11 C1x C 17.9200 -16.5200 12 C1x C 16.5200 -16.5200 13 C1y C 16.0300 -17.8500 14 N1x N 17.1500 -18.6900 15 C1c C 14.8400 -18.5500 16 C8y C 13.6500 -17.8500 17 C8x C 13.6500 -16.4500 18 C8x C 12.3900 -15.7500 19 C8x C 11.2000 -16.4500 20 C8x C 11.2000 -17.8500 21 C8x C 12.3900 -18.5500 22 O1a O 14.8400 -19.9500 23 C1y C 26.7400 -15.7500 24 O5a O 25.5500 -17.8500 25 C8x C 30.8700 -15.0500 26 C8x C 30.5200 -16.3800 27 C8y C 29.1200 -16.7300 28 N4y N 28.1400 -15.7500 29 C8y C 28.5600 -14.3500 30 N5x N 29.9600 -14.0700 31 O5x O 28.7700 -18.0600 32 C1x C 26.3200 -14.4900 33 C1x C 27.3700 -13.5800 BOND 37 1 1 2 1 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 6 7 1 7 7 8 2 8 3 8 1 9 6 9 1 10 10 9 1 #Up 11 10 11 1 12 11 12 1 13 12 13 1 14 13 14 1 #Up 15 10 14 1 16 15 16 1 17 15 13 1 18 16 17 2 19 17 18 1 20 18 19 2 21 19 20 1 22 20 21 2 23 16 21 1 24 15 22 1 #Down 25 23 1 1 #Down 26 1 24 2 27 25 26 2 28 26 27 1 29 27 28 1 30 28 29 1 31 29 30 2 32 25 30 1 33 27 31 2 34 28 23 1 35 32 33 1 36 29 33 1 37 32 23 1 |